Tanzeum granted FDA approval
SILVER SPRING, Md. — The Food and Drug Administration on Tuesday announced that it has approved Tanzeum (albiglutide) subcutaneous injection, which is used to improve glycemic control in adults with Type 2 diabetes.
Type 2 diabetes affects approximately 24 million people and accounts for more than 90% of diabetes cases diagnosed in the United States.
"Tanzeum is a new treatment option for the millions of Americans living with Type 2 diabetes," said Curtis Rosebraugh, M.D., M.P.H., director of the Office of Drug Evaluation II in the FDA’s Center for Drug Evaluation and Research. “It can be used alone or added to existing treatment regimens to control blood sugar levels in the overall management of diabetes.”
Tanzeum shouldn’t be used to treat people with Type 1 diabetes; those with increased ketones in their blood or urine; or as first-line therapy for patients who can’t be managed with diet and exercise.
L’Oréal Paris to kick off ‘Women of Worth’ program via all-day Twitter forum
NEW YORK — To kick-off the ninth annual Women of Worth program, L’Oréal Paris will convene thousands of women — including Maria Shriver, Arianna Huffington, Mika Brzezinski and L’Oreal Paris ambassadors Lea Michele, Eva Longoria and Liya Kebede — for the first-ever Women of Worth Twitter Forum on Wednesday. This day-long discussion will focus on the power of self-worth and its ability to propel women forward.
More than 40 years ago, L’Oréal Paris’ brand philosophy "Because I’m Worth It" was launched to celebrate women’s worth and self-esteem. This signature phrase was brought to life when L’Oréal Paris established Women of Worth to honor women making a beautiful difference in the world through volunteerism. Starting on Wednesday, nominations for the 2014 Women of Worth program will be accepted at WomenofWorth.com. The 10 women selected will be awarded $10,000, and one woman will be named the national honoree and awarded an additional $25,000 to further her philanthropic efforts. All 10 honorees will be recognized in December at a star-studded awards ceremony hosted by L’Oréal Paris in New York.
To celebrate the call for nominations and to ignite a discussion on the role of self-worth among women today, L’Oréal Paris is inviting all women to join the Women of Worth Twitter Forum on Wednesday. Women can join the conversation by following @LOrealParisUSA and tweeting during one of the five scheduled chats, using the hashtag #WomenofWorth:
- 9 a.m. ET: Women of Worth: Celebrating Extraordinary Women
- 1 p.m. ET: The Worth Effect: The Power of Giving Back
- 4 p.m. ET: Passion and Positivity: How Feeling Your Best Fuels Success
- 8 p.m. ET: The Beauty of Worth: Achieving Happiness in Life, Work and Love
- 9 p.m. ET: What’s Worth It: Charting Your Course & Realizing Your Dreams
"Celebrating the intrinsic beauty and worth of all women is the heart of the L’Oréal Paris brand, and we are deeply committed to championing women who are going above and beyond to serve their communities," said L’Oréal Paris President, Karen Fondu. "Worth has a multi-dimensional role in a woman’s life — it’s more than just confidence or self-esteem — it’s the foundation of everything we can and will achieve. The Women of Worth program was conceived as a way to demonstrate, through the achievements of incredible women, the impact of pursuing your passion and believing in your worth."
In a recent study commissioned by L’Oréal Paris on the power of self-worth, 81% of women agree that seeing other women give back inspires them to do the same. The study goes on to find that those giving back themselves tend to enjoy a stronger sense of self-worth.
Since 2006, L’Oréal Paris Women of Worth has recognized 80 women who have devoted themselves to causes at the local and national level and motivated others to get involved. The Women of Worth program is conducted in partnership with Points of Light, a volunteer service organization. Past honorees have been involved in a range of important causes from advocating for victims of childhood abuse and mentoring homeless youth, to helping break the cycle of poverty and empowering teens with disabilities.
Merck’s Grastek receives FDA approval
WHITEHOUSE STATION, N.J. — Merck announced that the Food and Drug Administration has approved Grastek (Timothy grass pollen allergen extract) tablet for sublingual use. The drug is an allergen extract used for the treatment of grass pollen-induced allergic rhinitis with or without conjunctivitis. It is approved for use in persons ages 5 years through 65 years of age.
“Every grass pollen season, many patients with moderate to severe allergic rhinitis experience nasal and ocular allergy symptoms at their worst while taking symptom-relieving medication,” said Dr. David Bernstein, professor of medicine and environmental health in the division of immunology, allergy and rheumatology at the University of Cincinnati College of Medicine. “These patients often have multiple sensitivities. Some of these patients may be candidates for immunotherapy, but decline allergy shots. With the FDA approval of Grastek, allergy specialists now have a new sublingual approach to offer these patients for their grass allergies.”
Timothy grass is one of the most common grass types in the United States, and has shown to be cross-reactive with other grasses, such as sweet vernal, orchard (or cocksfoot) and perennial rye, among others.